Adage Capital Partners
IMCR icon

Adage Capital Partners’s Immunocore IMCR Stock Holding History

Adage Capital Partners’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$1.37M – 916
2023
Q4 		$1.37M Buy
+20,000
New +$1.04M ﹤0.01% 756

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Adage Capital Partners's IMCR Position: Q1 2024 in Review

Adage Capital Partners sold out of Immunocore (IMCR) in Q1 2024, closing a stake of 20,000 shares — an estimated $1.37M sold.

Adage Capital Partners first reported a position in IMCR in Q4 2023 and held it in 1 quarter. The position peaked at $1.37M in Q4 2023. 149 funds tracked by Wall St. Rank hold IMCR as of Q1 2024.

  • Adage Capital Partners reported no remaining Immunocore position as of Q1 2024 after selling out during the quarter.
  • Adage Capital Partners sold 20,000 Immunocore shares in Q1 2024, an estimated $1.37M.
  • Adage Capital Partners first reported a position in Immunocore in Q4 2023 and held it in 1 quarter.
  • Adage Capital Partners's Immunocore position peaked at $1.37M in Q4 2023.
  • 149 funds tracked by Wall St. Rank held Immunocore as of Q1 2024.

Based on Adage Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.